84 related articles for article (PubMed ID: 20870344)
1. Synergistic effects of sonoporation and taurolidin/TRAIL on apoptosis in human fibrosarcoma.
Daigeler A; Chromik AM; Haendschke K; Emmelmann S; Siepmann M; Hensel K; Schmitz G; Klein-Hitpass L; Steinau HU; Lehnhardt M; Hauser J
Ultrasound Med Biol; 2010 Nov; 36(11):1893-906. PubMed ID: 20870344
[TBL] [Abstract][Full Text] [Related]
2. Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma.
Karlisch C; Harati K; Chromik AM; Bulut D; Klein-Hitpass L; Goertz O; Hirsch T; Lehnhardt M; Uhl W; Daigeler A
Int J Oncol; 2013 Mar; 42(3):945-56. PubMed ID: 23338823
[TBL] [Abstract][Full Text] [Related]
3. TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.
Daigeler A; Brenzel C; Bulut D; Geisler A; Hilgert C; Lehnhardt M; Steinau HU; Flier A; Steinstraesser L; Klein-Hitpass L; Mittelkötter U; Uhl W; Chromik AM
J Exp Clin Cancer Res; 2008 Dec; 27(1):82. PubMed ID: 19077262
[TBL] [Abstract][Full Text] [Related]
4. Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus.
Daigeler A; Chromik AM; Geisler A; Bulut D; Hilgert C; Krieg A; Klein-Hitpass L; Lehnhardt M; Uhl W; Mittelkötter U
Int J Oncol; 2008 Jun; 32(6):1205-20. PubMed ID: 18497982
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells.
Chromik AM; Daigeler A; Hilgert C; Bulut D; Geisler A; Liu V; Otte JM; Uhl W; Mittelkötter U
J Invest Surg; 2007; 20(6):339-48. PubMed ID: 18097875
[TBL] [Abstract][Full Text] [Related]
6. TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells.
Harati K; Chromik AM; Bulut D; Goertz O; Hahn S; Hirsch T; Klein-Hitpass L; Lehnhardt M; Uhl W; Daigeler A
Anticancer Res; 2012 Jul; 32(7):2967-84. PubMed ID: 22753761
[TBL] [Abstract][Full Text] [Related]
7. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2002 Feb; 128(2):73-9. PubMed ID: 11862476
[TBL] [Abstract][Full Text] [Related]
8. Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins.
Sun BS; Wang JH; Liu LL; Gong SL; Redmond HP
J Surg Oncol; 2007 Sep; 96(3):241-8. PubMed ID: 17469118
[TBL] [Abstract][Full Text] [Related]
9. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
Matsuzaki H; Schmied BM; Ulrich A; Standop J; Schneider MB; Batra SK; Picha KS; Pour PM
Clin Cancer Res; 2001 Feb; 7(2):407-14. PubMed ID: 11234897
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
11. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine.
Stendel R; Scheurer L; Stoltenburg-Didinger G; Brock M; Möhler H
Anticancer Res; 2003; 23(3B):2309-14. PubMed ID: 12894508
[TBL] [Abstract][Full Text] [Related]
13. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
16. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.
Abdollahi T; Robertson NM; Abdollahi A; Litwack G
Cancer Res; 2003 Aug; 63(15):4521-6. PubMed ID: 12907626
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
Sun J; Fu ZM; Fang CQ; Li JH
Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
[TBL] [Abstract][Full Text] [Related]
18. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
[TBL] [Abstract][Full Text] [Related]
19. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
20. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
